Sort by
Items per page

Send to

Choose Destination

Links from Books

Items: 1 to 20 of 119


Morphine enhances microglial migration through modulation of P2X4 receptor signaling.

Horvath RJ, DeLeo JA.

J Neurosci. 2009 Jan 28;29(4):998-1005. doi: 10.1523/JNEUROSCI.4595-08.2009.


The Neurontin legacy--marketing through misinformation and manipulation.

Landefeld CS, Steinman MA.

N Engl J Med. 2009 Jan 8;360(2):103-6. doi: 10.1056/NEJMp0808659. No abstract available.


Imaging of peripheral benzodiazepine receptor expression as biomarkers of detrimental versus beneficial glial responses in mouse models of Alzheimer's and other CNS pathologies.

Ji B, Maeda J, Sawada M, Ono M, Okauchi T, Inaji M, Zhang MR, Suzuki K, Ando K, Staufenbiel M, Trojanowski JQ, Lee VM, Higuchi M, Suhara T.

J Neurosci. 2008 Nov 19;28(47):12255-67. doi: 10.1523/JNEUROSCI.2312-08.2008.


Implication of activated astrocytes in the development of drug dependence: differences between methamphetamine and morphine.

Narita M, Suzuki M, Kuzumaki N, Miyatake M, Suzuki T.

Ann N Y Acad Sci. 2008 Oct;1141:96-104. doi: 10.1196/annals.1441.032. Review.


Identifying biological markers of activity in human nociceptive pathways to facilitate analgesic drug development.

Chizh BA, Greenspan JD, Casey KL, Nemenov MI, Treede RD.

Pain. 2008 Nov 30;140(2):249-53. doi: 10.1016/j.pain.2008.09.024. Epub 2008 Oct 23. Review. No abstract available.


Characterization of a cannabinoid CB2 receptor-selective agonist, A-836339 [2,2,3,3-tetramethyl-cyclopropanecarboxylic acid [3-(2-methoxy-ethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene]-amide], using in vitro pharmacological assays, in vivo pain models, and pharmacological magnetic resonance imaging.

Yao BB, Hsieh G, Daza AV, Fan Y, Grayson GK, Garrison TR, El Kouhen O, Hooker BA, Pai M, Wensink EJ, Salyers AK, Chandran P, Zhu CZ, Zhong C, Ryther K, Gallagher ME, Chin CL, Tovcimak AE, Hradil VP, Fox GB, Dart MJ, Honore P, Meyer MD.

J Pharmacol Exp Ther. 2009 Jan;328(1):141-51. doi: 10.1124/jpet.108.145011. Epub 2008 Oct 17.


Spinal cord histopathological alterations in a patient with longstanding complex regional pain syndrome.

Del Valle L, Schwartzman RJ, Alexander G.

Brain Behav Immun. 2009 Jan;23(1):85-91. doi: 10.1016/j.bbi.2008.08.004. Epub 2008 Aug 26.


Differential migration, LPS-induced cytokine, chemokine, and NO expression in immortalized BV-2 and HAPI cell lines and primary microglial cultures.

Horvath RJ, Nutile-McMenemy N, Alkaitis MS, Deleo JA.

J Neurochem. 2008 Oct;107(2):557-69. doi: 10.1111/j.1471-4159.2008.05633.x. Epub 2008 Sep 18.


Cannabinoid receptor CB2 localisation and agonist-mediated inhibition of capsaicin responses in human sensory neurons.

Anand U, Otto WR, Sanchez-Herrera D, Facer P, Yiangou Y, Korchev Y, Birch R, Benham C, Bountra C, Chessell IP, Anand P.

Pain. 2008 Sep 15;138(3):667-80. doi: 10.1016/j.pain.2008.06.007. Epub 2008 Aug 9.


Discovery and optimization of a novel series of N-arylamide oxadiazoles as potent, highly selective and orally bioavailable cannabinoid receptor 2 (CB2) agonists.

Cheng Y, Albrecht BK, Brown J, Buchanan JL, Buckner WH, DiMauro EF, Emkey R, Fremeau RT Jr, Harmange JC, Hoffman BJ, Huang L, Huang M, Lee JH, Lin FF, Martin MW, Nguyen HQ, Patel VF, Tomlinson SA, White RD, Xia X, Hitchcock SA.

J Med Chem. 2008 Aug 28;51(16):5019-34. doi: 10.1021/jm800463f. Epub 2008 Aug 5.


Cannabis and schizophrenia.

Rathbone J, Variend H, Mehta H.

Cochrane Database Syst Rev. 2008 Jul 16;(3):CD004837. doi: 10.1002/14651858.CD004837.pub2. Review. Update in: Cochrane Database Syst Rev. 2014;10:CD004837.


Neuroimmune interactions and pain: focus on glial-modulating targets.

Romero-Sandoval EA, Horvath RJ, DeLeo JA.

Curr Opin Investig Drugs. 2008 Jul;9(7):726-34. Review.


Efficacy of opioids for chronic pain: a review of the evidence.

Ballantyne JC, Shin NS.

Clin J Pain. 2008 Jul-Aug;24(6):469-78. doi: 10.1097/AJP.0b013e31816b2f26. Review.


A comparison of spinal Iba1 and GFAP expression in rodent models of acute and chronic pain.

Romero-Sandoval A, Chai N, Nutile-McMenemy N, Deleo JA.

Brain Res. 2008 Jul 11;1219:116-26. doi: 10.1016/j.brainres.2008.05.004. Epub 2008 May 11.


Increased binding of peripheral benzodiazepine receptor in Alzheimer's disease measured by positron emission tomography with [11C]DAA1106.

Yasuno F, Ota M, Kosaka J, Ito H, Higuchi M, Doronbekov TK, Nozaki S, Fujimura Y, Koeda M, Asada T, Suhara T.

Biol Psychiatry. 2008 Nov 15;64(10):835-41. doi: 10.1016/j.biopsych.2008.04.021. Epub 2008 Jun 2.


Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).

Pergolizzi J, Böger RH, Budd K, Dahan A, Erdine S, Hans G, Kress HG, Langford R, Likar R, Raffa RB, Sacerdote P.

Pain Pract. 2008 Jul-Aug;8(4):287-313. doi: 10.1111/j.1533-2500.2008.00204.x. Epub 2008 May 23.


The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain.

Staton PC, Hatcher JP, Walker DJ, Morrison AD, Shapland EM, Hughes JP, Chong E, Mander PK, Green PJ, Billinton A, Fulleylove M, Lancaster HC, Smith JC, Bailey LT, Wise A, Brown AJ, Richardson JC, Chessell IP.

Pain. 2008 Sep 30;139(1):225-36. doi: 10.1016/j.pain.2008.04.006. Epub 2008 May 27.


Neuroimaging of pain: advances and future prospects.

Stephenson DT, Arneric SP.

J Pain. 2008 Jul;9(7):567-79. doi: 10.1016/j.jpain.2008.02.008. Epub 2008 May 2. Review.


Opioids in the management of chronic non-cancer pain: an update of American Society of the Interventional Pain Physicians' (ASIPP) Guidelines.

Trescot AM, Helm S, Hansen H, Benyamin R, Glaser SE, Adlaka R, Patel S, Manchikanti L.

Pain Physician. 2008 Mar;11(2 Suppl):S5-S62. Review.

Supplemental Content

Support Center